Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | ACHE | P22303 | 1/20 | 0.35 |
| ▸ | BACE1 | P56817 | 1/20 | 0.35 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20550450 | 1.00 | CA1 (0.37) | CA1CA2ACHEBACE1EPHX1 | |
| SCHEMBL17768031 | 0.79 | CA2 (0.43) | CA1CA2ACHEBACE1EPHX1 | |
| SCHEMBL16754663 | 0.79 | CA2 (0.43) | CA1CA2ACHEBACE1EPHX1 | |
| Hydrochloric Acid SCHEMBL20550683 | 0.77 | CA2 (0.42) | CA1CA2ACHEBACE1EPHX1 | |
| Hydrochloric Acid SCHEMBL20550684 | 0.77 | CA2 (0.42) | CA1CA2ACHEBACE1EPHX1 | |
| SCHEMBL20550608 | 0.74 | FPR2 (0.39) | CA1CA2ACHEBACE1EPHX1 | |
| SCHEMBL20550607 | 0.74 | FPR2 (0.39) | CA1CA2ACHEBACE1EPHX1 | |
| SCHEMBL29152379 | 0.72 | FAAH (0.49) | — | |
| SCHEMBL433771 | 0.72 | FAAH (0.49) | — | |
| SCHEMBL433772 | 0.72 | FAAH (0.49) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3221317-B1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE IP NO 2 LTD (GB) | 2020-07-22 | — | — | EP | claimed |
| US-20180319810-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE IP NO 2 LTD (GB) | 2018-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180319810-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | SIRT1, SIRT3, SIRT2 | CA1 4563/4885CA2 4152/4885ACHE 2300/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.